Omics research in lymphangioleiomyomatosis: status and challenges.

IF 2.9 3区 医学 Q2 RESPIRATORY SYSTEM Expert Review of Respiratory Medicine Pub Date : 2024-09-11 DOI:10.1080/17476348.2024.2403498
Xinhe Zhang,Song Liu,Luning Yang,Chongsheng Cheng,Hanghang Wang,Danjing Hu,Xiaoxin Zhang,Miaoyan Zhang,Yaping Liu,Xinlun Tian,Hongbing Zhang,Kai-Feng Xu
{"title":"Omics research in lymphangioleiomyomatosis: status and challenges.","authors":"Xinhe Zhang,Song Liu,Luning Yang,Chongsheng Cheng,Hanghang Wang,Danjing Hu,Xiaoxin Zhang,Miaoyan Zhang,Yaping Liu,Xinlun Tian,Hongbing Zhang,Kai-Feng Xu","doi":"10.1080/17476348.2024.2403498","DOIUrl":null,"url":null,"abstract":"INTRODUCTION\r\nLymphangioleiomyomatosis (LAM) is a rare and progressive disorder that usually arises in the lung and almost exclusively affects women of childbearing age. In recent years, a number of molecules have been shown to be differentially expressed between patients with LAM and healthy control individuals, and some of these molecules, in addition to vascular endothelial growth factor D (VEGF-D), have the potential to be novel biomarkers.\r\n\r\nAREAS COVERED\r\nThis review summarizes the recent advances in omics research, including genomics, transcriptomics, proteomics, and metabolomics, in LAM biomarker discovery. It also retrieves the literature on LAM biomarkers studied by omics techniques in the last ten years using PubMed and other retrieval tools.\r\n\r\nEXPERT OPINION\r\nFurther research on expanded sample sizes can be conducted to construct specific models to study the role of these molecules in the pathogenesis of LAM and clarify the underlying mechanisms involved. In the future, in terms of technology, the combination of various omics methods is expected to result in novel biomarker discovery.","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":"60 1","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Respiratory Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17476348.2024.2403498","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

INTRODUCTION Lymphangioleiomyomatosis (LAM) is a rare and progressive disorder that usually arises in the lung and almost exclusively affects women of childbearing age. In recent years, a number of molecules have been shown to be differentially expressed between patients with LAM and healthy control individuals, and some of these molecules, in addition to vascular endothelial growth factor D (VEGF-D), have the potential to be novel biomarkers. AREAS COVERED This review summarizes the recent advances in omics research, including genomics, transcriptomics, proteomics, and metabolomics, in LAM biomarker discovery. It also retrieves the literature on LAM biomarkers studied by omics techniques in the last ten years using PubMed and other retrieval tools. EXPERT OPINION Further research on expanded sample sizes can be conducted to construct specific models to study the role of these molecules in the pathogenesis of LAM and clarify the underlying mechanisms involved. In the future, in terms of technology, the combination of various omics methods is expected to result in novel biomarker discovery.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
淋巴管瘤病的 Omics 研究:现状与挑战。
导言淋巴管瘤(LAM)是一种罕见的进行性疾病,通常发生在肺部,几乎只影响育龄妇女。近年来,一些分子被证明在 LAM 患者和健康对照者之间有差异表达,其中一些分子,除了血管内皮生长因子 D (VEGF-D),还有可能成为新型生物标记物。专家观点可以通过扩大样本量开展进一步研究,构建特定模型来研究这些分子在 LAM 发病机制中的作用,并阐明相关的潜在机制。未来,在技术方面,各种 omics 方法的结合有望发现新的生物标记物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.80
自引率
2.60%
发文量
90
期刊介绍: Coverage will include the following key areas: - Prospects for new and emerging therapeutics - Epidemiology of disease - Preventive strategies - All aspects of COPD, from patient self-management to systemic effects of the disease and comorbidities - Improved diagnostic methods, including imaging techniques, biomarkers and physiological tests. - Advances in the treatment of respiratory infections and drug resistance issues - Occupational and environmental factors - Progress in smoking intervention and cessation methods - Disease and treatment issues for defined populations, such as children and the elderly - Respiratory intensive and critical care - Updates on the status and advances of specific disease areas, including asthma, HIV/AIDS-related disease, cystic fibrosis, COPD and sleep-disordered breathing morbidity
期刊最新文献
Non-invasive respiratory support in elderly hospitalized patients. Overcoming challenges of managing chronic obstructive pulmonary disease in low- and middle-income countries Understanding the impact of breathing pattern disorders in difficult-to-treat asthma Omics research in lymphangioleiomyomatosis: status and challenges. A clinician's guide to effects of obesity on childhood asthma and into adulthood.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1